AEterna Zentaris to Present at BIO 2005 in Philadelphia
June 09 2005 - 8:30AM
PR Newswire (US)
AEterna Zentaris to Present at BIO 2005 in Philadelphia QUEBEC
CITY, June 9 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX:
AEZ; NASDAQ: AEZS) announced that Gilles Gagnon, President and
Chief Executive Officer of the Company, will present a corporate
update on Monday, June 20, 2005, at 4:45 p.m. (local time) in Room
E of the Pennsylvania Convention Centre in Philadelphia. About
AEterna Zentaris Inc. AEterna Zentaris Inc. is an oncology and
endocrine therapy focused biopharmaceutical company with proven
expertise in drug discovery, development and marketing. The
Company's broad 20 product pipeline leverages six different
therapeutic approaches, including LHRH antagonists and signal
transduction inhibitors. The lead LHRH antagonist compound,
cetrorelix, is currently marketed for in vitro fertilization under
the brand name Cetrotide(R). Cetrorelix is also in late-stage
clinical development for endometriosis and benign prostatic
hyperplasia (BPH). The lead signal transduction inhibitor compound,
perifosine, is a novel, first-in-class, oral anticancer agent that
modulates several key signal transduction pathways, including AKT,
MAPK, and JNK that have been shown to be critical for the survival
of cancer cells. Perifosine has demonstrated single agent
anti-tumor activity in Phase I and Phase II studies and is
currently being studied as a single agent and in combination with
several forms of anti-cancer treatments for various forms of
cancer, including non-small cell lung cancer and breast cancer.
AEterna Zentaris also owns 50.3% of Atrium Biotechnologies Inc.
(TSX: ATB.sv), a leading developer, manufacturer and marketer of
value-added products for the cosmetics, pharmaceutical, chemical
and nutritional industries. News releases and additional
information are available at http://www.aeternazentaris.com/ .
DATASOURCE: AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES
LABORATOIRES AETERNA CONTACT: Media Relations: Paul Burroughs,
(418) 652-8525 ext. 406, ; Investor Relations: Ginette Vallieres,
(418) 652-8525 ext. 265, ; Europe: Matthias Seeber, +49 69 42602
3425, ; To request a free copy of this organization's annual
report, please go to http://www.newswire.ca/ and click on
reports@cnw
Copyright